TROMBOEMBOLISMO PULMONAR: Tratamiento del tromboembolismo pulmonar sintomático con rivaroxabán oral

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

Contenido principal del artículo

Carlos Sánchez, MD.
Darío Londoño Trujillo, MD., MSc.

Detalles del artículo

Biografía del autor/a (VER)

Carlos Sánchez, MD., Hospital Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá, Colombia.

Internista, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá, Colombia.

Darío Londoño Trujillo, MD., MSc., Hospital Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá, Colombia.

Internista, Neumólogo, Jefe de Neumología, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá, Colombia.

Referencias (VER)

Silverstein MD, Heit JA. Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 111. Trends in the incidence of deep veln thrombosis and pulmonary embolism: a 25-year population-based study. Arch lntern Med. 1998; 158: 585-93.

Oger E. lncidence of venous thromboembolism: a community-based study in western France Thromb Haemost 2000; 83: 657-60.

Eichinger S, et al. Thrombosis or pulmonary embolism: the Vienna prediction model risk assessment of recurrence in patients with unprovoked deep vein. Circulalion 2010; 121: 1630-1636.

Douketis JO et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann lntern Med. 2007; 147: 766-774.

Ridker PM, et al. Long-term, low-lntensity warfarin therapy for the prevention of recurrent venous thromboembollsm. N Engl J Med. 2003; 348: 1425-1434.

Kearon C. Kahn SR. Agnelli G. Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease· American College of Chest Physicians Evidence-Based Clinical Practice Gurdelrnes (8th Edition). Chest. 2008; 133: 4548-5458

Büller HR, GallusAS, Pillion G, Prins MH, Raskob GE. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary ernbolism: a randomised, double-blind, doubfe-dummy, non-inferiority trial. Lancet 2012; 379: 123-9.

The van Gogh lnvestigators. ldraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007; 357: 1094-104.

Agnelli G, Buller HR, Cohen A, et al. apixaban for extended treatment of venous thromboembollsm. N Engl J Med. 2013; 368: 699-708.